(Q44074835)

29 November 2017

Spectrum of disease in U.S. veteran patients with hepatitis C. (English)

1 reference

29 November 2017

0 references

0 references

Huy A Nguyen

1

1 reference

29 November 2017

April I Miller

2

1 reference

29 November 2017

Eric Dieperink

3

1 reference

29 November 2017

Mark L Willenbring

4

1 reference

29 November 2017

Lori L Tetrick

5

1 reference

29 November 2017

Janet M Durfee

6

1 reference

29 November 2017

Stephen L Ewing

7

1 reference

29 November 2017

Samuel B Ho

8

1 reference

29 November 2017

language of work or name

English

0 references

publication date

1 July 2002

1 reference

The American Journal of Gastroenterology

29 November 2017

1 reference

29 November 2017

97

1 reference

29 November 2017

7

1 reference

29 November 2017

1813-1820

1 reference

Alpha-glutathione transferases in HCV-related chronic hepatitis: a new predictive index of response to interferon therapy?

29 November 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05800.X

Risk factors for the rising rates of primary liver cancer in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05800.X

The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05800.X

Epidemiology of hepatitis C virus infection in American veterans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05800.X

Prevalence of hepatitis C virus seropositivity among hospitalized US veterans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05800.X

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05800.X

Impact of alcohol on the histological and clinical progression of hepatitis C infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05800.X

Influence of psychiatric diagnoses on interferon-alpha treatment for chronic hepatitis C in a veteran population

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05800.X

Efficacy of daily induction dosing vs standard thrice weekly dosing of interferon-alpha2B for initial treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05800.X

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05800.X

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05800.X

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05800.X

The natural history of hepatitis C virus infection: host, viral, and environmental factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05800.X

Benefits of linking primary medical care and substance abuse services: patient, provider, and societal perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05800.X

A randomized trial of integrated outpatient treatment for medically ill alcoholic men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05800.X

Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05800.X

Treatment of hepatitis C infection in injection drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05800.X

A 33-year follow-up of narcotics addicts

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05800.X

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05800.X

Peginterferon alfa-2a in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05800.X

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05800.X

10.1111/J.1572-0241.2002.05800.X

21 January 2018

Identifiers

DOI

1 reference

29 November 2017

1 reference